Drug Trial Radar · NCT03694197
Long Term Safety Study of PRALUENT
Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,389
Actual
Start
Sep 28, 2018
Primary completion
Apr 8, 2020
Study completion Apr 8, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682). The secondary objectives of the study were: * To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C) * To evaluate the effect of PRALUENT on other lipid parameters * To evaluate the effect of PRALUENT on gonadal steroid hormones
Conditions
- Heterozygous Familial Hypercholesterolemia
- Non-familial Hypercholesterolemia
Interventions
PraluentDrug
Subcutaneous (SC) administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 WeeksTime frame: After first administration of study drug through the last dose of study drug plus 2 weeks, up to 80 weeks
Locations
123 sites in 6 countries. Site status is shown where the registry gives one.
Regeneron Research Site
Auburn, Alabama
Regeneron Research Site
Mobile, Alabama
Regeneron Research Site
Beverly Hills, California
Regeneron Research Site
Los Gatos, California
Regeneron Research Site
North Hollywood, California
Regeneron Research Site
Port Hueneme, California
Regeneron Research Site
Aurora, Colorado
Regeneron Research Site
Colorado Springs, Colorado
Regeneron Research Site
Lake Worth, Florida
Regeneron Research Site
Miami Springs, Florida
Regeneron Research Site
Champaign, Illinois
Regeneron Research Site
Evansville, Indiana
Regeneron Research Site
Indianapolis, Indiana
Regeneron Research Site
Ames, Iowa
Regeneron Research Site
Iowa City, Iowa
Regeneron Research Site
Waterloo, Iowa
Regeneron Research Site
Newton, Kansas
Regeneron Research Site
Louisville, Kentucky
Regeneron Research Site
Bangor, Maine
Regeneron Research Site
Baltimore, Maryland
Regeneron Research Site
Oxon Hill, Maryland
Regeneron Research Site
Olive Branch, Mississippi
Regeneron Research Site
Washington, Missouri
Regeneron Research Site
Buffalo, New York
Regeneron Research Site
New Hyde Park, New York
Regeneron Research Site
Cary, North Carolina
Regeneron Research Site
Charlotte, North Carolina
Regeneron Research Site
Charlotte, North Carolina
Regeneron Research Site
Greensboro, North Carolina
Regeneron Research Site
Hickory, North Carolina
Regeneron Research Site
Raleigh, North Carolina
Regeneron Research Site
Rocky Mount, North Carolina
Regeneron Research Site
Salisbury, North Carolina
Regeneron Research Site
Statesville, North Carolina
Regeneron Research Site
Wilmington, North Carolina
Regeneron Research Site
Winston-Salem, North Carolina
Regeneron Research Site
Cincinnati, Ohio
Regeneron Research Site
Cleveland, Ohio
Regeneron Research Site
Dayton, Ohio
Regeneron Research Site
Charleston, South Carolina
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.